Transcript Please enter title of conference, maximum 2 lines, optimum

Pharmaceutical Industry
and Boehringer Ingelheim
Pharmaceutical Industry Leader in Fairfield County
Paul Fonteyne
Executive Vice President
Head of Marketing & Sales, Prescription
Medicines
Ridgefield, Connecticut
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential
2
Background
• Founded in 1885 in Ingelheim, Germany
• World’s largest family-owned pharmaceutical company
• Operates worldwide
- 156 affiliated companies in over 60 countries
• Focus: Human Pharmaceuticals (95%) and Animal Health
• Products in a variety of therapeutic areas
- Cardiovascular, Respiratory, CNS, Virology, Oncology, Immunology, Urology,
Rheumatology, GI/Metabolic
• Research focused
- Medicines for those diseases where genuine therapeutic innovation can be
demonstrated.
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential
3
Worldwide - 2004
•Total Net Sales
-Human Pharma
-Animal Health
$ 10.2 Billion
96%
4%
•Total Employees
nearly 36,000
•R&D+C Expenditures
$ 1.23 Billion
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential
4
Top 20 Corporations 2004
Global Pharma Market
in EUR billion
40
37.8
35
30
25
20
23.4
19.5
18.3
17.8
15
10
5
16.3
15.9
12.4
11.2
10.4
10.3
9.3
7.9
6.8
6.1
4.9
4.5
3.9
3.7
3.4
Source: IMS Health, IMS Health / MAT Q4 2004
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential
5
Top 20 Corporations ranked
by Growth
MAT to Q4 2004 in Constant Euro
Boehringer Ingelheim Growth Rate above Top 20
Corporations (+8.2%)
in %
30
25
25.5
20
15
10
14.3
10.2
9.4
9.2
5
-5
9.0
9.0
8.4
8.0
7.3
6.4
6.1
5.8
4.7
3.5
1.8
1.3
-1.2
-3.9
-10
-15
-13.2
-20
Source: IMS Health, IMS Health / MAT Q4 2004
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential
6
Prescription Medicines
Our Six Highlights
flomax®
mobic®
micardis®
viramune®
spiriva®
mirapex®
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential
7
Ridgefield Campus Projects
• Lead Discovery Technologies Building dedicated in 2001
• Kilo Lab
• Completed in 2005, produces drug substances up to 5 kg quantities for
research purposes.
• On-site Child Care Center; September 2006
• 19,000 sq ft stand alone building with a capacity for 256 infants, toddlers and
preschoolers.
• Physical Sciences building; March 2007
• 86,000 sq ft building to accommodate relocation of our cardiovascular
diseases research program from Germany.
• 3 floors, 119 work stations for scientists and management.
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential
8
BI Cares Foundation
The Foundation’s mission is to improve lives through innovative
philanthropic contributions and donations of healthcare products and
resources.
• BI Cares Foundation Patient Assistance Plan (170,000 patients
expected to be enrolled in 2005)
• Hurricane Rita and Katrina assistance
• Product Donation Program ($160M in product donation
anticipated in 2005)
• Cash contributions in 2004 - $1.9M
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential
9
Community Involvement - CT
•
•
•
•
•
•
•
•
•
•
•
•
Lung Health Screening Program
United Way of Northern Fairfield County
Regional Hospice of Western Connecticut
American Red Cross
Connecticut PBS – Family Science Expo
Abilities Beyond Disabilities (DATAHR)
Connecticut United for Research Excellence
Ives Center for the Arts
Girl Scout Council of SW Connecticut
Regional YMCA Center for Arts & Humanities
Special Olympics – Connecticut
Western Connecticut State University
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential
10
Pharmaceutical Industry
Challenges - Government
• Prescription drug importation
• AKA price controls
• Promotion restrictions
• Lower market penetration of new products
• Increased costs of doing business
• Energy, taxes, fees, liability
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential
11
Pharmaceutical Industry
Challenges - Industry
• Continued innovation
• Continued ability to fund R&D
• Cost of and time to develop new products
• Attracting talented, highly educated workforce
• Continue to effectively and efficiently serve a diverse and changing
marketplace
• Physicians, patients, institutions, payors
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential
12
Summary
• BI is a growing, innovative pharmaceutical company and employer in
Fairfield County
• BI is committed to delivering value to patients and to the healthcare
community
• Challenges to the healthcare marketplace and pharmaceutical
industry are significant
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential
13
Web information
• http://www.boehringer-ingelheim.com
Worldwide web
• http://us.boehringer-ingelheim.com
US company web
• https://www.pparx.org/Intro.php
Partnership for
Prescription Assistance
• http://us.boehringeringelheim.com/about/philanthropy/Patient_Assistance_Program.html
BI Cares Foundation
Patient Assistance web
Boehringer Ingelheim Pharmaceuticals, Inc. - Confidential
14
Pharmaceutical Industry
and Boehringer Ingelheim
Pharmaceutical Industry Leader in Fairfield County
Paul Fonteyne
Executive Vice President
Head of Marketing & Sales, Prescription
Medicines